BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27443325)

  • 1. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence.
    Banerjee M; Wiebel JL; Guo C; Gay B; Haymart MR
    BMJ; 2016 Jul; 354():i3839. PubMed ID: 27443325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
    Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
    J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation.
    Peiling Yang S; Bach AM; Tuttle RM; Fish SA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1561-7. PubMed ID: 25632970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer.
    Wiebel JL; Esfandiari NH; Papaleontiou M; Worden FP; Haymart MR
    Thyroid; 2015 Sep; 25(9):1026-32. PubMed ID: 26133765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
    Schvartz C; Bonnetain F; Dabakuyo S; Gauthier M; Cueff A; Fieffé S; Pochart JM; Cochet I; Crevisy E; Dalac A; Papathanassiou D; Toubeau M
    J Clin Endocrinol Metab; 2012 May; 97(5):1526-35. PubMed ID: 22344193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
    Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
    J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.
    Ruhlmann M; Binse I; Bockisch A; Rosenbaum-Krumme SJ
    Nuklearmedizin; 2016 Jun; 55(3):99-103. PubMed ID: 26830084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET).
    Kist JW; de Keizer B; van der Vlies M; Brouwers AH; Huysmans DA; van der Zant FM; Hermsen R; Stokkel MP; Hoekstra OS; Vogel WV; ;
    J Nucl Med; 2016 May; 57(5):701-7. PubMed ID: 26609180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in imaging after diagnosis of thyroid cancer.
    Wiebel JL; Banerjee M; Muenz DG; Worden FP; Haymart MR
    Cancer; 2015 May; 121(9):1387-94. PubMed ID: 25565063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatment.
    Pelttari H; Laitinen K; Schalin-Jäntti C; Välimäki MJ
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):323-31. PubMed ID: 18284635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
    Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
    Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioactive iodine in differentiated thyroid cancer: a national database perspective.
    Orosco RK; Hussain T; Noel JE; Chang DC; Dosiou C; Mittra E; Divi V; Orloff LA
    Endocr Relat Cancer; 2019 Oct; 26(10):795-802. PubMed ID: 31443087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Free Survival in Patients With Differentiated Thyroid Cancer.
    Banerjee M; Reyes-Gastelum D; Haymart MR
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2720-2727. PubMed ID: 29788217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 18fluoro-2-deoxyglucose positron emission tomography in iodine scan negative, differentiated thyroid cancer recurrence.
    Chisholm EJ; Tolley NS
    J Laryngol Otol; 2009 Oct; 123(10):1145-9. PubMed ID: 19607742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer.
    Seiboth L; Van Nostrand D; Wartofsky L; Ousman Y; Jonklaas J; Butler C; Atkins F; Burman K
    Thyroid; 2008 Feb; 18(2):103-11. PubMed ID: 18279011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
    Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
    Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.